

Marianna Adamo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4241610/publications.pdf>

Version: 2024-02-01

133
papers

11,002
citations

136950

32
h-index

36028

97
g-index

136
all docs

136
docs citations

136
times ranked

10265
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
2	Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, 2020, 5, 819.	6.1	1,465
3	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
4	Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. European Heart Journal, 2020, 41, 1821-1829.	2.2	434
5	<scp>COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. European Journal of Heart Failure, 2020, 22, 957-966.	7.1	208
6	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	2.9	135
7	Highlights in heart failure. ESC Heart Failure, 2019, 6, 1105-1127.	3.1	109
8	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 941-956.	7.1	95
9	The "Ten Commandments" of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2022, 43, 440-441.	2.2	95
10	Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair. American Heart Journal, 2015, 170, 187-195.	2.7	90
11	Chimney Stenting for Coronary Occlusion During TAVR. JACC: Cardiovascular Interventions, 2020, 13, 751-761.	2.9	90
12	Treatment of functional mitral regurgitation in chronic heart failure: can we get a "proof of concept" from the MITRA-ER and COAPT trials?. European Journal of Heart Failure, 2019, 21, 852-861.	7.1	82
13	COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. Frontiers in Cardiovascular Medicine, 2021, 8, 713560.	2.4	76
14	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. Journal of Heart and Lung Transplantation, 2020, 39, 1353-1362.	0.6	75
15	COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation. JACC: Cardiovascular Interventions, 2021, 14, 15-25.	2.9	70
16	Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation. JACC: Cardiovascular Interventions, 2021, 14, 1-11.	2.9	59
17	Transcatheter Self-Expandable Valve Implantation for Aortic Stenosis in Small Aortic Annuli. JACC: Cardiovascular Interventions, 2020, 13, 196-206.	2.9	54
18	Heart failure in the last year: progress and perspective. ESC Heart Failure, 2020, 7, 3505-3530.	3.1	52

#	ARTICLE	IF	CITATIONS
19	Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry. <i>American Heart Journal</i> , 2019, 217, 32-41.	2.7	50
20	Italian Society of Interventional Cardiology (<sc>Glse</sc>) registry Of Transcatheter treatment of mitral valve regurgitation (<sc>GIOTTO</sc>): impact of valve disease aetiology and residual mitral regurgitation after <sc>MitraClip</sc> implantation. <i>European Journal of Heart Failure</i> , 2021, 23, 1364-1376.	7.1	49
21	Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry. <i>European Journal of Heart Failure</i> , 2019, 21, 196-204.	7.1	47
22	Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience. <i>International Journal of Cardiology</i> , 2017, 234, 53-57.	1.7	45
23	Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis. <i>European Heart Journal</i> , 2020, 41, 1876-1886.	2.2	45
24	A Score to Assess Mortality After Percutaneous Mitral Valve Repair. <i>Journal of the American College of Cardiology</i> , 2022, 79, 562-573.	2.8	44
25	Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2018, 269, 33-39.	1.7	42
26	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 143-168.	7.1	41
27	Comparison of Three Contemporary Surgical Scores for Predicting All-Cause Mortality of Patients Undergoing Percutaneous Mitral Valve Repair With the MitraClip System (from the Multicenter) <i>Tj ETQq1 1 0.784314 rgBT /Qørlock</i>		
28	Predictors and Clinical Impact of Prosthesis-Patient Mismatch After Self-Expandable TAVR in Small Annuli. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1218-1228.	2.9	40
29	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Espanola De Cardiología</i> , 2022, 75, 523.e1-523.e114.	1.2	40
30	Direct transcatheter aortic valve implantation with self-expandable bioprosthesis: Feasibility and safety. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 200-203.	0.8	38
31	Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 874-881.	1.5	38
32	Transcatheter mitral valve repair in patients with acute myocardial infarction: insights from the European Registry of MitraClip in Acute Mitral Regurgitation following an acute myocardial infarction (EREMMI). <i>EuroIntervention</i> , 2020, 15, 1248-1250.	3.2	38
33	Transcatheter aortic valve implantation with the new repositionable self-expandable Evolut R versus CoreValve system: A case-matched comparison. <i>International Journal of Cardiology</i> , 2017, 243, 126-131.	1.7	37
34	Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction. <i>European Heart Journal</i> , 2022, 43, 641-650.	2.2	36
35	Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair. <i>EuroIntervention</i> , 2020, 16, 413-420.	3.2	35
36	Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. <i>EuroIntervention</i> , 2016, 11, e1222-e1230.	3.2	35

#	ARTICLE	IF	CITATIONS
37	Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2408-2421.	2.8	34
38	A meta-analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients. <i>ESC Heart Failure</i> , 2018, 5, 1150-1158.	3.1	32
39	Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 1750-1758.	7.1	32
40	Incidence, Technical Safety, and Feasibility of Coronary Angiography and Intervention Following Self-expanding Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 371-375.	0.8	29
41	Use of MitraClip for mitral valve repair in patients with acute mitral regurgitation following acute myocardial infarction: Effect of cardiogenic shock on outcomes (IREMMI Registry). <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1259-1267.	1.7	29
42	Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 201, 179-181.	1.7	26
43	Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comers PRODIGY trial. <i>International Journal of Cardiology</i> , 2016, 212, 110-117.	1.7	26
44	Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. <i>ESC Heart Failure</i> , 2022, 9, 1507-1523.	3.1	26
45	Impact of COVID-19 pandemic and infection on in hospital survival for patients presenting with acute coronary syndromes: A multicenter registry. <i>International Journal of Cardiology</i> , 2021, 332, 227-234.	1.7	24
46	Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (Glse) Registry Of Transcatheter Treatment of Mitral Valve Regurgitation (GIOTTO). <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1057-1062.	0.8	23
47	Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk?. <i>European Heart Journal</i> , 2020, 41, 3094-3094.	2.2	23
48	Role of different vascular approaches on transcatheter aortic valve implantation outcome. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 279-285.	1.5	21
49	Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients: Incidence and Predictors of 2-Year Good Outcome. <i>Canadian Journal of Cardiology</i> , 2022, 38, 320-329.	1.7	20
50	Effectiveness of MitraClip Therapy in Patients with Refractory Heart Failure. <i>Journal of Interventional Cardiology</i> , 2015, 28, 61-68.	1.2	19
51	Appropriateness of percutaneous coronary interventions in patients with ischaemic HEart disease in Italy: the APACHE pilot study. <i>BMJ Open</i> , 2017, 7, e016909.	1.9	16
52	Use of edge-to-edge percutaneous mitral valve repair for severe mitral regurgitation in cardiogenic shock: A multicenter observational experience (MITRA-SHOCK study). <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E163-E170.	1.7	16
53	Mitraclip therapy in patients with functional mitral regurgitation and missing leaflet coaptation: is it still an exclusion criterion?. <i>European Journal of Heart Failure</i> , 2016, 18, 1278-1286.	7.1	15
54	Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation. <i>European Journal of Heart Failure</i> , 2021, 23, 1765-1774.	7.1	13

#	ARTICLE	IF	CITATIONS
55	Congestion in Patients with Advanced Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 575-586.	2.1	13
56	Self-expanding transcatheter aortic valve implantation for degenerated small Mitroflow bioprosthesis: early and midterm outcomes. <i>EuroIntervention</i> , 2017, 13, e1032-e1039.	3.2	13
57	Prognostic Significance of Change in the Left Ventricular Ejection Fraction After Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis and Left Ventricular Dysfunction. <i>American Journal of Cardiology</i> , 2017, 120, 1639-1647.	1.6	12
58	Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey. <i>EuroIntervention</i> , 2016, 12, 1154-1163.	3.2	12
59	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 275-300.	1.8	11
60	Predictors of optimal procedural result after transcatheter edge-to-edge mitral valve repair in secondary mitral regurgitation. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1626-1635.	1.7	11
61	Transaxillary versus transaortic approach for transcatheter aortic valve implantation with CoreValve Revalving System: insights from multicenter experience. <i>Journal of Cardiovascular Surgery</i> , 2017, 58, 747-754.	0.6	10
62	ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19. <i>European Heart Journal</i> , 2020, 41, 3200-3200.	2.2	10
63	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	3.3	10
64	Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature. <i>ESC Heart Failure</i> , 2021, 8, 4717-4736.	3.1	9
65	Left Atrial Volume Index and Outcome after Transcatheter Edge-to-Edge Valve Repair for Secondary Mitral Regurgitation. <i>European Journal of Heart Failure</i> , 0, , .	7.1	9
66	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1667-1676.	2.9	8
67	Comparison of Early and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with New York Heart Association Functional Class IV to those in Class III and Less. <i>American Journal of Cardiology</i> , 2018, 122, 1718-1726.	1.6	8
68	Interaction between severe chronic kidney disease and acute kidney injury in predicting mortality after transcatheter aortic valve implantation: Insights from the Italian Clinical Service Project. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1500-1508.	1.7	8
69	Prognostic Value of Pre-operative Atrial Fibrillation in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation. <i>American Journal of Cardiology</i> , 2021, 143, 51-59.	1.6	8
70	Characteristics and outcomes of MitraClip in octogenarians: Evidence from 1853 patients in the GIOTTO registry. <i>International Journal of Cardiology</i> , 2021, 342, 65-71.	1.7	8
71	Percutaneous Edge-to-Edge Mitral Valve Repair: Beyond the Left Heart. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 1038-1045.	2.8	7
72	Observed versus predicted mortality after MitraClip treatment in patients with symptomatic heart failure and significant functional mitral regurgitation. <i>European Journal of Heart Failure</i> , 2018, 20, 1495-1496.	7.1	6

#	ARTICLE	IF	CITATIONS
73	Percutaneous valve repair of functional mitral regurgitation: aiming at optimal and durable results. <i>European Journal of Heart Failure</i> , 2020, 22, 1849-1851.	7.1	6
74	Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction. <i>Journal of Clinical Medicine</i> , 2021, 10, 1819.	2.4	6
75	Implantation of one, two or multiple MitraClip [®] for transcatheter mitral valve repair: insights from a 1824-patient multicenter study. <i>Panminerva Medica</i> , 2022, 64, .	0.8	6
76	Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 439-446.	1.5	6
77	Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. <i>International Journal of Cardiology</i> , 2015, 190, 242-245.	1.7	5
78	Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1418-1428.	1.2	5
79	June 2020 at a glance: focus on COVID-19, quality of life and comorbidities. <i>European Journal of Heart Failure</i> , 2020, 22, 917-918.	7.1	5
80	Patient with heart failure: importance to treat valvular diseases. <i>European Heart Journal Supplements</i> , 2020, 22, P38-P41.	0.1	5
81	EkoSonic Endovascular System for patients with acute pulmonary embolism and contraindication to systemic fibrinolysis. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 131-136.	1.5	4
82	January 2020 at a glance: translational medicine, predictors of outcome and treatments. <i>European Journal of Heart Failure</i> , 2020, 22, 1-2.	7.1	4
83	March 2021 at a glance: focus on epidemiology, prevention and COVID-19. <i>European Journal of Heart Failure</i> , 2021, 23, 347-349.	7.1	4
84	Clinical outcomes and predictors in patients with previous cardiac surgery undergoing mitral valve transcatheter edge-to-edge repair. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 100, 451-460.	1.7	4
85	OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolonged Bivalirudin Infusion. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 934-936.	5.3	3
86	May 2020 at a glance: ischaemic heart failure and sex-related differences. <i>European Journal of Heart Failure</i> , 2020, 22, 761-762.	7.1	3
87	The effect of transcatheter aortic valve implantation approaches on mortality. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1462-1469.	1.7	3
88	Right ventricular deformation and right ventricular-arterial coupling in patients with heart failure due to severe aortic stenosis undergoing TAVI: long-term results. <i>American Journal of Cardiovascular Disease</i> , 2020, 10, 150-163.	0.5	3
89	Effect of Chronic Kidney Disease on 5-Year Outcome in Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Percutaneous MitraClip Insertion. <i>American Journal of Cardiology</i> , 2022, 171, 105-114.	1.6	3
90	Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse) <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1156-1171.	1.7	2

#	ARTICLE	IF	CITATIONS
91	Renal failure after trans-catheter aortic valve implantation. <i>European Journal of Internal Medicine</i> , 2021, 83, 86-87.	2.2	2
92	Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy. <i>European Journal of Heart Failure</i> , 2021, 23, 486-488.	7.1	2
93	December 2020 at a glance: focus on COVID-19, comorbidities and palliative care. <i>European Journal of Heart Failure</i> , 2020, 22, 2173-2174.	7.1	2
94	Sarcopenia detected by computed tomography: a simple tool for screening transcatheter aortic valve implantation candidates. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 69-70.	1.5	2
95	December 2019 at a glance: economic burden, comorbidities, and prognosis. <i>European Journal of Heart Failure</i> , 2019, 21, 1485-1486.	7.1	1
96	Prognostic Impact of Heart Failure History in Patients with Secondary Mitral Regurgitation Treated by MitraClip. <i>American Journal of Cardiology</i> , 2020, 135, 120-127.	1.6	1
97	November 2020 at a glance: focus on comorbidities and medical treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1937-1938.	7.1	1
98	March 2020 at a glance: heart failure with preserved ejection fraction, left atrial myopathy, atrial fibrillation and cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2020, 22, 389-390.	7.1	1
99	Life-saving transcatheter aortic valve implantation for acute severe aortic regurgitation due to rheumatoid arthritis and complicated by cardiogenic shock. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 268-271.	1.5	1
100	Impact of optical coherence tomography findings on clinical outcomes in ST-segment elevation myocardial infarction patients: a MATRIX (Minimizing Adverse Hemorrhagic Events by Trans-radial) Trial. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 1143-1150.	1.5	1
101	Can mild to moderate secondary mitral regurgitation be a therapeutic target for symptomatic patients with heart failure with reduced ejection fraction?. <i>European Journal of Heart Failure</i> , 2021, 23, 1979-1980.	7.1	1
102	Highlights in valvular heart diseases. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 925-926.	1.5	1
103	Risk stratification in cardiogenic shock: from clinical utility to improving outcomes. <i>European Journal of Heart Failure</i> , 2022, 24, 668-671.	7.1	1
104	March 2022 at a glance: focus on medical therapy, prevention and comorbidities. <i>European Journal of Heart Failure</i> , 2022, 24, 403-405.	7.1	1
105	Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 792804.	2.4	1
106	September 2019 at a glance: focus on devices. <i>European Journal of Heart Failure</i> , 2019, 21, 1049-1050.	7.1	0
107	October 2019 at a glance: epidemiology, prevention, and modes of death. <i>European Journal of Heart Failure</i> , 2019, 21, 1167-1168.	7.1	0
108	November 2019 at a glance. Chronic and acute heart failure: from epidemiology to treatment. <i>European Journal of Heart Failure</i> , 2019, 21, 1297-1298.	7.1	0

#	ARTICLE	IF	CITATIONS
109	July 2020 at a glance: focus on imaging and cardiomyopathies. European Journal of Heart Failure, 2020, 22, 1057-1059.	7.1	0
110	September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy. European Journal of Heart Failure, 2020, 22, 1493-1494.	7.1	0
111	August 2020 at a glance: focus on neurohormonal antagonists and electrolytes. European Journal of Heart Failure, 2020, 22, 1289-1290.	7.1	0
112	October 2020 at a glance: focus on outcomes, valve disease and patients' monitoring. European Journal of Heart Failure, 2020, 22, 1745-1746.	7.1	0
113	February 2020 at a glance: acute heart failure and cardio-oncology. European Journal of Heart Failure, 2020, 22, 171-172.	7.1	0
114	Percutaneous treatment of mitral regurgitation: looking for a final model. Internal and Emergency Medicine, 2020, 15, 13-15.	2.0	0
115	April 2020 at a glance: epidemiology, prevention, and biomarkers. European Journal of Heart Failure, 2020, 22, 570-571.	7.1	0
116	January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity. European Journal of Heart Failure, 2021, 23, 1-2.	7.1	0
117	February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy. European Journal of Heart Failure, 2021, 23, 201-202.	7.1	0
118	April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure. European Journal of Heart Failure, 2021, 23, 505-506.	7.1	0
119	May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 691-692.	7.1	0
120	June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment. European Journal of Heart Failure, 2021, 23, 847-849.	7.1	0
121	July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy. European Journal of Heart Failure, 2021, 23, 1059-1061.	7.1	0
122	Treatment of secondary mitral regurgitation in patients with heart failure: when left ventricular ejection fraction may become not crucial. EuroIntervention, 2021, 17, e271-e273.	3.2	0
123	August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices. European Journal of Heart Failure, 2021, 23, 1247-1249.	7.1	0
124	Cardiac output in severe tricuspid regurgitation: when more is less. European Journal of Heart Failure, 2021, 23, 1795-1797.	7.1	0
125	September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment. European Journal of Heart Failure, 2021, 23, 1419-1421.	7.1	0
126	October 2021 at a glance: focus on imaging, biomarkers and comorbidities. European Journal of Heart Failure, 2021, 23, 1569-1571.	7.1	0

#	ARTICLE	IF	CITATIONS
127	Reply: Explaining differing outcomes from the COAPT and MITRA-FR trials using disproportionate and proportionate secondary mitral regurgitation. EuroIntervention, 2020, 16, e777-e778.	3.2	0
128	November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices. European Journal of Heart Failure, 2021, 23, 1803-1805.	7.1	0
129	January 2022 at a glance: time for the new <scp>ESC</scp> guidelines on heart failure. European Journal of Heart Failure, 2022, 24, 1-3.	7.1	0
130	December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models. European Journal of Heart Failure, 2021, 23, 1993-1994.	7.1	0
131	464â€¦Implantation of contemporary transcatheter aortic valves in small aortic annuli: the international multicentre TAVI-SMALL 2 registry. European Heart Journal Supplements, 2021, 23, .	0.1	0
132	April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 593-595.	7.1	0
133	May 2022 at a glance. Focus on treatment: from epidemiologic data to randomized trials and new devices. European Journal of Heart Failure, 2022, 24, 735-737.	7.1	0